C-reactive protein is elevated in schizophrenia

Schizophrenia Research

Volumn 143, Issue 1, 2013, Pages 198-202

  Dickerson, Faith ^a   Stallings, Cassie ^a   Origoni, Andrea ^a   Vaughan, Crystal ^a   Khushalani, Sunil ^a   Yang, Shuojia ^b   Yolken, Robert ^b  

^a Stanley Research Program   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; C reactive protein; Inflammatory marker; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN;

ACADEMIC ACHIEVEMENT; ADULT; AGE DISTRIBUTION; ARTICLE; BIPOLAR DISORDER; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RACE DIFFERENCE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; C-REACTIVE PROTEIN; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84871929199     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.041     Document Type: Article

References (36)

1. Akanji A.O., Ohaeri J.U., Al-Shammri S., Fatania H.R. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. 2009, 169(1):56-61.
2. Azar M., Valentin E., Badaoui G., Kassab R., Sarkis A., Azar R.R. Comparison of the effects of combination atorvastatin (40mg)+ezetimibe (10mg) versus atorvastatin (40mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am. J. Cardiol. 2011, 107(11):1571-1574.
3. Brown A.S. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 2011, 93(1):23-58.
4. de Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005, 76(2-3):135-157.
5. Diaz F.J., Pérez-Iglesias R., Mata I., Martínez-Garcia O., Vázquez-Barquero J.L., de Leon J., Crespo-Facorro B. Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. Schizophr. Res. 2010, 121(1-3):207-212.
6. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., Yolken R.H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 2003, 60(5):466-472.
7. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(4):952-955.
8. Dickerson F., Stallings C., Sullens A., Origoni A., Leister F., Krivogorsky B., Yolken R. Association between cognitive functioning, exposure to herpes simplex virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. Brain Behav. Immun. 2008, 22(7):1103-1107.
9. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Leister F., Yang S., Krivogorsky B., Alaedini A., Yolken R. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol. Psychiatry 2010, 68(1):100-104.
10. Dieset I., Hope S., Ueland T., Bjella T., Agartz I., Melle I., Aukrust P., Røssberg J.I., Andreassen O.A. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr. Res. 2012, 140(1-3):169-174.
11. Fawzi M.H., Fawzi M.M., Fawzi M.M., Said N.S. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011, 190(1):91-97.
12. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194(5):434-438.
13. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W. User's Guide for the SCID-I, Structured Clinical Interview for DSM IV Axis I Disorders 1996, Biometrics Research, New York.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders - Non-patient Edition (SCID-I/NP) 1998, Biometrics Research, New York.
15. Gejman P.V., Sanders A.R., Kendler K.S. Genetics of schizophrenia: new findings and challenges. Annu. Rev. Genomics Hum. Genet. 2011, 12:121-144.
16. Hope S., Melle I., Aukrust P., Steen N.E., Birkenaes A.B., Lorentzen S., Agartz I., Ueland T., Andreassen O.A. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 2009, 11(7):726-734.
17. Kay S.R. Positive and Negative Syndromes in Schizophrenia: Assessment and Research 1991, Bruner/Mazel, New York.
18. Khera A., McGuire D.K., Murphy S.A., Stanek H.G., Das S.R., Vongpatanasin W., Wians F.H., Grundy S.M., de Lemos J.A. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 2005, 46:464-499.
19. Lowe G.D. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J. Thromb. Haemost. 2005, (8):1618-1627.
20. Megna J.L., Schwartz T.L., Siddiqui U.A., Herrera, Rojas M. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Ann. Clin. Psychiatry 2011, 23(2):131-140.
21. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., Hsiao J.K., Swartz M.S., Stroup T.S., Lieberman J.A. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol. Psychiatry 2009, 66(11):1013-1022.
22. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
23. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia: an integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
24. Osman R., L'Allier P.L., Elgharib N., Tardif J.C. Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc. Health Risk Manag. 2006, 2(3):221-237.
25. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res. Clin. Pract. 2005, 69(1):29-35.
26. Rexrode K.M., Pradhan A., Manson J.E., Buring J.E., Ridker P.M. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 2003, 13(10):674-682.
27. Richard M.D., Brahm N.C. Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am. J. Health Syst. Pharm. 2012, 69(9):757-766.
28. Rubin D.B. Multiple imputation after 18+ years. J. Am. Stat. Assoc. 1996, 91:473-489.
29. Sharpe J.K., Stedman T.J., Byrne N.M., Hills A.P. Low-fat oxidation may be a factor in obesity among men with schizophrenia. Acta Psychiatr. Scand. 2009, 119(6):451-456.
30. Sicras-Mainar A., Rejas-Gutiérrez J., Navarro-Artieda R., Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur. Psychiatry 2011, (Sep 30. (Epub ahead of print)).
31. Suvisaari J., Loo B.M., Saarni S.E., Haukka J., Perälä J., Saarni S.I., Viertiö S., Partti K., Lönnqvist J., Jula A. Inflammation in psychotic disorders: a population-based study. Psychiatry Res. 2011, 189(2):305-311. (Sep 30).
32. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 2008, 102(1-3):1-18.
33. The International Schizophrenia Consortium, Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
34. Wannamethee S.G., Lowe G.D.O., Shaper A.G., Rumley A., Lennon L., Whincup P.H. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur. Heart J. 2005, 26:1765-1773.
35. Wener M.H., Daum P.R., McQuillan G.M. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J. Rheumatol. 2000, 27(10):2351-2359.
36. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler. Thromb. Vasc. Biol. 1999, 19(4):972-978.